Thermo Fisher Scientific Inc. (TMO) is making robust progress with its growth strategy, which bodes well for the upcoming quarters. The spree of innovative product introductions bolsters its portfolio. The company's Bioproduction business is expanding and increasing its capacity to meet the rising demand. Meanwhile, the adverse macroeconomic impacts and currency fluctuations raise concerns for TMO's operations, In the past year, shares of this Zacks Rank #3 (Hold) company have rallied 20.7% compared with th ...

Thermo Fisher Scientific Inc. (NYSE: TMO ) has been one of the best-performing stocks over the last decade, with shares returning more than 420% over this period. I've written about investing for Seeking Alpha since 2015 and for Sure Dividend since 2018. I focus primarily on owning shares of companies that have demonstrated long histories of dividend growth. These types of companies have largely proven successful at raising dividends through multiple recessionary periods, a sign that their business models a ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Thermo Fisher Scientific (TMO) , which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider. When looking at the last two reports, this maker of scientific instrument and laboratory supplies has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 6.70%, on average, in the ...

Thermo Fisher Scientific (TMO) announced the launch of the international CorEvitas Adolescent Atopic Dermatitis (AD) Registry, designed to study novel treatments for the most common inflammatory skin condition in adolescent patients. The registry fills a significant gap for real-world evidence and adolescentspecific developmental and safety data related to novel therapies for AD, complementing the existing adult CorEvitas AD Registry launched in 2020. CorEvitas, acquired in August 2023, is part of Thermo Fi ...

Strong electron microscopy growth and strategic buyouts are likely to drive Thermo Fisher Scientific's (TMO) growth. Yet, macroeconomic issues and currency fluctuations continue to dampen business growth. The stock carries a Zacks Rank #3 (Hold) currently. Factors Driving Growth for TMO Stock Within the pharma and biotech end market, of late, Thermo Fisher's biosciences and bioproduction businesses have significantly expanded their capacity to meet the global vaccine manufacturing requirements. The pharma s ...

Thermo Fisher Scientific's (TMO) PPD clinical research business has expanded its global laboratory services by opening a new bioanalytical lab in GoCo Health Innovation City in Gothenburg, Sweden. The 29,000- square-foot facility will serve pharmaceutical and biotech customers with advanced laboratory services and cutting-edge instrumentation across all phases of pharmaceutical development to help deliver life-changing medicines to patients worldwide. The latest development furthers the company's strategy t ...

Biognosys' Spectronaut®, the leading vendor-agnostic software for DIA proteomics, is now directly available from Thermo Fisher Scientific under a reselling agreement End users can get access to Thermo Scientific mass spectrometry systems and Biognosys' Spectronaut software via a single offer issued by Thermo Fisher Thermo Fisher will directly quote and sell Biognosys' Spectronaut software from its product catalog ZURICH and NEWTON, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leading inventor and ...

Thermo Fisher Scientific (NYSE:TMO) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 8:30 AM ET Company Participants Marc Casper - Chairman, President and CEO Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant Hey, everyone. Good morning. I'm Tejas Savant. I cover life sciences here at Morgan Stanley. Before we kick it off, for important disclosures, please see the Morgan Stanley Research disclosure website at morganstanley.com/researchdisclosures. And if you ha ...

Thermo Fisher Scientific Inc. (TMO) is gaining investors' confidence due to its impressive partnerships. Of late, the company has launched a slew of products to enhance its portfolio. However, declining COVID-19 testing-related demand, as well as adverse macroeconomic impacts might deter Thermo Fisher's growth. Year to date, this Zacks Rank #3 (Hold) company's shares have rallied 15.7% compared with 7.8% growth of the industry. The S&P 500 composite has risen 17.6% during the said time frame. The renowned m ...

isak55/iStock via Getty Images Introduction Thermo Fisher Scientific Inc (TMO) Total Return SPDR® S&P 500® ETF Trust (SPY) Total Return 229.33 The Health Care Select Sector SPDR® ETF (XLV) Total Return 0.00% -200.0% 2016 2018 2020 2022 2024 Seeking AlphaQ Jul 27, 2024, 5:05 AM EDT Po esed by YCHARTS Data by YCharts A Future-Proof Business Model Not only does the healthcare sector come with anti-cyclical demand and secular growth, but it also helps to improve the lives of countless people. Before the Industi ...